跳至主要内容
临床试验/IRCT20120215009014N486
IRCT20120215009014N486尚未招募3 期

Evaluation of the effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in non-diabetic patients with systolic heart failure: a double-blind randomized clinical trial

Hamedan University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • Age 18 to 80 years
  • Controlled systolic heart failure for at least 6 months
  • Hemoglobin A1c less than 6.5
  • Stable clinical and hemodynamic status

排除标准

  • Pregnancy or breastfeeding
  • Inflammatory, respiratory, infectious or malignant diseases
  • History of myocardial infarction, stroke, angioplasty or CABG in the last 3 months
  • Embedding pacemaker in the last 3 months
  • Use of anti-oxidant or anti-inflammatory drugs or corticosteroids in the last 3 months

研究者

相似试验